A 'biosimilar' is a biotherapeutic product that has provensimilarity in terms of quality, safety and efficacy to a licensed reference product (RP) ( Table 1 ). The term 'biosimilar' was introduced for biologics because their complexity makes it impossible to make an identical copy. In contrast, a 'generic' is an exact copy of a small-molecule drug with a known chemical structure and a fixed number of atoms. With patent expiries of biologics, biosimilars have been proclaimed as a means to broaden access to treatment and reduce costs.
In addition to guidelines published by the World Health Organization (WHO) in 2009, 1 biosimilar development is strictly regulated by the US Food and Drug Administration (FDA), 2 and the European Medicines Agency (EMA) 3 (Table 1 ). These organizations require that similarity to a RP should be demonstrated by performing comprehensive comparability studies that confirm pharmaceutical quality, biological activity, safety (including immunogenicity) and efficacy.
Development of biosimilar guidelines in regions with high regulatory
vigilance, such as the European Union (EU), the USA, and more recently in Japan, Canada and Australia, has contributed to increased usage of biosimilars among healthcare professionals (HCPs). However, guideline adoption in regions such as Latin America, Asia and non-EU countries remains slow, and a historical lack of regulatory scrutiny in these areas has led to the controversial approval of so-called "Non-Comparable BioTherapeutics" (NCBTs) that do not comply with established standards for biosimilar approval. In this article, we present early experience in rare diseases following the introduction of NCBTs for Gaucher disease (GD) and consider the wider implications for the treatment of rare diseases.
| NON-COMPARABLE BIOTHERAPEUTICS ARE NOT BIOSIMILARS
Biosimilars and NCBTs may differ from the RP across a variety of important structural and functional elements including glycosylation and purity. However, unlike for biosimilars, approval of NCBTs (also known as "biomimics" or "intended copies") is usually based on "shortcut" regulatory pathways where limited clinical and comparability data to a RP is considered. In this situation, these differences may have important implications for drug efficacy and patient safety. 4 For example, NCBTs for recombinant erythropoietins have been associated with adverse immunological effects leading to pure red cell aplasia (PRCA). 5 Furthermore, whereas WHO, FDA and EMA biosimilar guidelines require the use of a unique naming system that enables prescribers to distinguish between a biosimilar and its RP (Table 1) , short-cut regulatory pathways for NCBTs may permit the use of the 
| GAUCHER DISEASE (GD), A RARE DISEASE EXAMPLE
Gaucher disease is a rare, inherited lysosomal storage disease that affects 1 in 40 000 to 60 000 people, depending on ethnicity. 6 It is caused by biallelic mutations in the gene that encodes lysosomal glucocerebrosidase (GBA). It is characterized by an accumulation of glucosylceramide in macrophages of the liver, spleen and bone marrow leading to multiple manifestations, including hepatosplenomegaly, anemia, thrombocytopenia, growth retardation and skeletal disease.
Three types of GD exist; GD types 2 and 3 can be distinguished from type 1 by the presence of CNS involvement. Gaucher disease is progressive, with long-term complications such as osteonecrosis and malignancy. Clinical and radiological evidence of diverse bone involvement occurs in the majority of patients even in the absence of significant hematological and visceral abnormalities, underscoring GD heterogeneity and the need for long-term monitoring.
Gaucher disease type 1 was the first disease to be successfully treated with Enzyme Replacement Therapy (ERT), initially in 1991 with placentalderived glucocerebrosidase (alglucerase, Ceredase ® , Genzyme The effectiveness of ERT for Gaucher disease requires selective, However, no data has been published or presented for this product. Authors of the Phase 2 study initially referred to Abcertin as a "biosimilar" for Cerezyme. 9 Although they have since corrected their claim in an erratum to their initial publication, confusion could persist regarding the precise nature of Abcertin. 10 Thirdly, glycosylation profiles should be fully characterized for all biologics, as this can contribute to their immunogenicity, potency, specific activity and biodistribution. 7 An additional critical consideration is the use of a unique naming identifier that differentiates between biologic products to ensure traceability, and to avoid confusion at the prescribing and dispensing level as well as among patients.
There is an urgent need for improved education and awareness among HCPs, and patients involved in rare diseases, on the differences between RPs, biosimilars and NCBTs, including regulatory requirements, terminology and requirements for long-term monitor- 
